Oman Journal of Ophthalmology

REVIEW ARTICLE
Year
: 2008  |  Volume : 1  |  Issue : 1  |  Page : 3--6

Vascular endothelial growth factor blocking agents in retinal vein occlusion


Chris Canning 
 Moorfields Eye Hospital, Dubai, United Arab Emirates

Correspondence Address:
Chris Canning
Medical Director, Moorfields Eye Hospital, Dubai
United Arab Emirates

This paper summarises the current status of the use of vascular endothelial growth factor (VEGF) blocking agents in retinal vein occlusion. There have been no randomised controlled trials comparing this treatment with the current standard treatment (largely laser) so the lower grade evidence of single treatment case series and anecdotal reports are discussed. VEGF blockers are good at reducing macular oedema in the short term, do improve visual acuity in many cases, and do not seem to adversely affect the long term revascularisation that is necessary to overcome the vein occlusion. VEGF blocking agents are not used in isolation in this condition - they will remain an adjunct to systemic and other local treatments. The literature was reviewed in online searches of Embase and Ovid and the papers quoted are a representative sample of a larger body of publications.


How to cite this article:
Canning C. Vascular endothelial growth factor blocking agents in retinal vein occlusion.Oman J Ophthalmol 2008;1:3-6


How to cite this URL:
Canning C. Vascular endothelial growth factor blocking agents in retinal vein occlusion. Oman J Ophthalmol [serial online] 2008 [cited 2020 Aug 3 ];1:3-6
Available from: http://www.ojoonline.org/article.asp?issn=0974-620X;year=2008;volume=1;issue=1;spage=3;epage=6;aulast=Canning;type=0